SPINK1 and colorectal carcinoma: In conclusion, these data suggest that sustained inhibition of not only MAPK pathway activation, but also ATF‐4 and trypsin, might be beneficial in the therapy of BRAF V600E‐mutant CRC and that SPINK1 levels may serve as an indicator of therapy response.